There is substantial evidence to show that in the staging of non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) there is a good concordance between 18FDG PET and whole-body CT (20). Moreover,18FDG PET can detect more sites of disease compared with conventional assessment (52-54). However, in the majority of patients, conventional assessment including whole-body CT is all that is necessary for planning treatment.18FDG PET is relevant in the subgroup of patients where there is a clinical need for clarification between localized disease and disseminated disease. Included in this group are those patients where there is a clinical suspicion of disseminated disease that cannot be confirmed by conventional techniques or when imaging suggests widespread disease that is not apparent clinically (48).18FDG PET however cannot consistently detect foci of low-grade NHL and foci of mucosal associated lymphoid tissue (MALT) lymphoma (55,56). Other issues which occasionally occur when 18FDG PET is used for staging of lymphoma include physiological uptake in bowel which mimics mesenteric nodal disease and distinguishing between sarcoidosis and lymphoma as both pathologies can result in intense abnormal 18FDG PET uptake in lymph nodes.

0 0

Post a comment